PTC Therapeutics Inc is now accepting applications for the 2021 STRIVE Awards Program for Duchenne muscular dystrophy. The deadline to apply is March 15. Winners will be announced in September 2021.
New for the 7th annual awards program is an entry category dedicated to supporting programs that focus on the transition of those living with Duchenne from adolescence to adulthood, PTC Therapeutics Inc notes in a media release.
“The new award category recognizes the recent progressions seen in the treatment and management of Duchenne, with many individuals now living longer, fulfilled lives as adults – a milestone that seemed unachievable just a few years ago. However, this improvement in care creates new challenges, and guidance and support from local organizations will be critical to helping these individuals smoothly navigate the transition to adulthood.”
— Mary Frances Harmon, Senior Vice President, Corporate Relations, PTC Therapeutics
Until recently, children with Duchenne did not usually live beyond their teens. However, improvements in cardiac and respiratory care mean that life expectancy is increasing, with many Duchenne patients now reaching their 30s and 40s. As a result of this, there is an increasing emphasis on quality of life and psychosocial support for the Duchenne community, meaning there is an urgent need to coordinate and improve the transition from childhood to adulthood.
Since inception, the STRIVE program has supported over 30 patient initiatives from not-for-profit organizations around the world. Winning programs have improved access to diagnosis and treatment; created career opportunities for adults with Duchenne; raised awareness of Duchenne in educational, public and healthcare settings; and provided emotional and physical support to caregivers, the release explains.
For more information about the program and previous recipients, as well as guidance and support with writing grant entries, visit PTC Therapeutics Inc.
[Source(s): PTC Therapeutics Inc, PR Newswire]